[go: up one dir, main page]

WO2008090960A1 - ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 - Google Patents

ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 Download PDF

Info

Publication number
WO2008090960A1
WO2008090960A1 PCT/JP2008/050994 JP2008050994W WO2008090960A1 WO 2008090960 A1 WO2008090960 A1 WO 2008090960A1 JP 2008050994 W JP2008050994 W JP 2008050994W WO 2008090960 A1 WO2008090960 A1 WO 2008090960A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibody composition
genetically recombinant
recombinant antibody
ganglioside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/050994
Other languages
English (en)
French (fr)
Inventor
Kenya Shitara
Rinpei Niwa
Akito Natsume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to US12/524,215 priority Critical patent/US20110236374A1/en
Priority to JP2008555105A priority patent/JPWO2008090960A1/ja
Priority to EP08703821A priority patent/EP2107115A1/en
Publication of WO2008090960A1 publication Critical patent/WO2008090960A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　本発明は、ヒトIgG1抗体において、Fc領域中のCH2ドメインを含むポリペプチドが、KabatらによるEUインデックスにおいてヒトIgG3抗体の同じ位置に相当するアミノ酸配列からなるポリペプチドに置換された、ヒトIgG1抗体およびヒトIgG3抗体よりも高い補体依存性細胞傷害活性を示す、ガングリオシドGM2に特異的に結合する遺伝子組換え抗体組成物、該遺伝子組換え抗体組成物に含まれる抗体分子または該抗体分子の重鎖定常領域をコードするDNA、該DNAを宿主細胞に導入して得られる形質転換体、該形質転換体を用いた遺伝子組換え抗体組成物の生産方法、ならびに該抗体組成物を有効成分として含有する医薬に関する。
PCT/JP2008/050994 2007-01-24 2008-01-24 ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 Ceased WO2008090960A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/524,215 US20110236374A1 (en) 2007-01-24 2008-01-24 Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
JP2008555105A JPWO2008090960A1 (ja) 2007-01-24 2008-01-24 ガングリオシドｇｍ２に特異的に結合する遺伝子組換え抗体組成物
EP08703821A EP2107115A1 (en) 2007-01-24 2008-01-24 Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007013641 2007-01-24
JP2007-013641 2007-05-23

Publications (1)

Publication Number Publication Date
WO2008090960A1 true WO2008090960A1 (ja) 2008-07-31

Family

ID=39644534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050994 Ceased WO2008090960A1 (ja) 2007-01-24 2008-01-24 ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物

Country Status (4)

Country Link
US (1) US20110236374A1 (ja)
EP (1) EP2107115A1 (ja)
JP (1) JPWO2008090960A1 (ja)
WO (1) WO2008090960A1 (ja)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010018846A1 (ja) * 2008-08-13 2010-02-18 協和発酵キリン株式会社 ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
WO2012073985A1 (ja) * 2010-11-30 2012-06-07 中外製薬株式会社 細胞傷害誘導治療剤
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
KR20150090107A (ko) * 2012-12-06 2015-08-05 도쿠리츠다이가쿠호징 가나자와다이가쿠 중피종의 치료 방법
PL2953634T3 (pl) 2013-02-07 2021-11-22 The General Hospital Corporation Sposoby namnażania lub zubożania limfocytów t-regulatorowych
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
CN117903308A (zh) 2016-05-13 2024-04-19 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59140885A (ja) 1983-01-13 1984-08-13 マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ 植物細胞ゲノムへの発現可能な遺伝子の導入法
JPS6070080A (ja) 1983-02-24 1985-04-20 レイクスニベルシテイト　ライデン 双子葉植物の染色体への外来性ｄνａの組込方法
JPS60251887A (ja) 1984-05-11 1985-12-12 ノバルティス　アクチエンゲゼルシャフト 植物のプロトプラストの形質転換法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPS63309192A (ja) 1987-02-17 1988-12-16 ファーミング　ビーブイ 効率的な分泌のための乳腺に出される蛋白におけるｄｎａ配列
EP0327378A1 (en) 1988-02-05 1989-08-09 The Trustees Of Columbia University In The City Of New York Domain-modified constant region antibodies
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH04311385A (ja) 1991-04-10 1992-11-04 Kyowa Hakko Kogyo Co Ltd ハイブリドーマの製造法
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994000977A1 (fr) 1992-07-07 1994-01-20 Japan Tobacco Inc. Procede de transformation d'une monocotyledone
EP0598998A2 (en) 1992-09-07 1994-06-01 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies reacting with the ganglioside GM2
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
JP2517813B2 (ja) 1990-05-29 1996-07-24 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 生きている細胞に生物学的物質を導入するための改良された方法および装置
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
JP2606856B2 (ja) 1986-12-05 1997-05-07 アグラシータス 生細胞中に遺伝物質担持担体粒子を注入するための装置
JPH10257893A (ja) 1997-03-19 1998-09-29 Kyowa Hakko Kogyo Co Ltd ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US20030158389A1 (en) 1998-04-02 2003-08-21 Genentech, Inc. Polypeptide variants
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20050054832A1 (en) 2002-03-01 2005-03-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2007011041A1 (ja) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物
WO2010055993A1 (ko) 2008-11-11 2010-05-20 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59140885A (ja) 1983-01-13 1984-08-13 マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ 植物細胞ゲノムへの発現可能な遺伝子の導入法
JPS6070080A (ja) 1983-02-24 1985-04-20 レイクスニベルシテイト　ライデン 双子葉植物の染色体への外来性ｄνａの組込方法
JPS60251887A (ja) 1984-05-11 1985-12-12 ノバルティス　アクチエンゲゼルシャフト 植物のプロトプラストの形質転換法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JP2606856B2 (ja) 1986-12-05 1997-05-07 アグラシータス 生細胞中に遺伝物質担持担体粒子を注入するための装置
JPS63309192A (ja) 1987-02-17 1988-12-16 ファーミング　ビーブイ 効率的な分泌のための乳腺に出される蛋白におけるｄｎａ配列
EP0327378A1 (en) 1988-02-05 1989-08-09 The Trustees Of Columbia University In The City Of New York Domain-modified constant region antibodies
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP2517813B2 (ja) 1990-05-29 1996-07-24 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 生きている細胞に生物学的物質を導入するための改良された方法および装置
JPH04311385A (ja) 1991-04-10 1992-11-04 Kyowa Hakko Kogyo Co Ltd ハイブリドーマの製造法
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994000977A1 (fr) 1992-07-07 1994-01-20 Japan Tobacco Inc. Procede de transformation d'une monocotyledone
EP0598998A2 (en) 1992-09-07 1994-06-01 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies reacting with the ganglioside GM2
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
JPH10257893A (ja) 1997-03-19 1998-09-29 Kyowa Hakko Kogyo Co Ltd ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
US20030158389A1 (en) 1998-04-02 2003-08-21 Genentech, Inc. Polypeptide variants
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US20050054832A1 (en) 2002-03-01 2005-03-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2007011041A1 (ja) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物
WO2010055993A1 (ko) 2008-11-11 2010-05-20 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법

Non-Patent Citations (242)

* Cited by examiner, † Cited by third party
Title
"A Laboratory Manual", 1992, W. H. FREEMAN AND COMPANY, article "Current Protocols in Molecular Biology; Baculovirus Expression Vectors"
"A Laboratory Manual", 1992, W.H. FREEMAN AND COMPANY, article "Current Protocols in Molecular Biology; Baculovirus Expression Vectors"
"Antibodies, A Laboratory manual", 1988, COLD SPRING HARBOR LABORATORY, article "Current Protocols in Molecular Biology"
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY
"Antibody Engineering, A Practical Approach", 1996, IRL PRESS AT OXFORD UNIVERSITY PRESS
"Biochemical Experimentation Methods 23 - Method for Studying Glycoprotein Sugar Chain", 1989, JAPAN SCIENTIFIC SOCIETIES PRESS
"Biomanual Series 4 - Methods of Gene Transfer, Expression and Analysis", 1994, YODOSHA
"Biomanual Series 8", 1995, YODOSHA, article "Gene Targeting, Preparation of Mutant Mice Using ES Cells"
"cDNA Cloning", 1996, YODOSHA
"Cell Technology", 1996, article "Experimental Protocol Series, Glycobiology Experimental Protocol, Glycoprotein, Glycolipid and Proteoglycan"
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
"Current Protocols in Molecular Biology; A Laboratory Manual", 1989
"Developmental Engineering Experimentation Manual - Preparation of Transgenic Mice", 1987, KODANSHA
"DNA Cloning 1: Core Techniques, A Practical Approach", 1995, OXFORD UNIVERSITY
"Enzyme Antibody Technique", 1985, GAKUSAI KIKAKU
"Enzyme Immunoassay", 1987, IGAKU SHOIN
"Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS
"Manipulating the Mouse Embryo, A Laboratory Manual", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS, article "Gene Targeting, A Practical Approach"
"Manipulating the Mouse Embryo, A Laboratory Manual", 1994, COLD SPRING HARBOR LABORATORY PRESS
"Methods for Preparing Gene Libraries", 1994, YODOSHA
"Molecular Cloning"
"Molecular Cloning", 1987, article "Current Protocols in Molecular Biology"
"Molecular Cloning", article "Current Protocols in Molecular Biology"
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LAB. PRESS
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"Molecular Cloning, A Laboratory Manual", vol. 1-34, 1989, COLD SPRING HARBOR LAB. PRESS, article "Current Protocols in Molecular Biology"
"Molecular Cloning, A Laboratory Manual", vol. 1-34, 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Current Protocols in Molecular Biology"
"Molecular Cloning, Second Edition, Current Protocols in Molecular Biology"
"Monoclonal Antibodies: Principles and Applications", 1995, WILEY-LISS, INC.
"Monoclonal Antibodies: principles and practice", 1993, ACAD. PRESS
"Monoclonal Antibodies: Principles and Practice", 1996, ACADEMIC PRESS LIMITED
"PCR Protocols", 1990, ACADEMIC PRESS
"Seibutsukagaku Jikkenho", vol. 23, 1989, GAKKAI SHUPPAN CENTER, article "Totanpakushitsu Tosa Kenkyuho"
"Sequence of Proteins of Immunological Interest", 1991
"Sequences of Proteins of Immunological Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES
"Shin Seikagaku Jikken Koza", 1988
"Soshiki Baiyo no Gijutsu", 1996, ASAKURA SHOTEN
AGRIC. BIOL. CHERN., vol. 55, no. 1, 1991, pages 283 - 284
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, 1996, pages 627S
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, 1996, pages 639S
ANAL. BIOCHEM., vol. 171, 1988, pages 73
ANALYTICAL BIOCHEMISTRY, vol. 162, 1987, pages 156
ANN. ALLERGY ASTHMA IMMUNOL., vol. 81, 1998, pages 105
BENTLEY K. J. ET AL., HYBRIDOMA, vol. 17, 1998, pages 559 - 567
BIO/TECHNOLOGY, vol. 17, 1999, pages 1097
BIO/TECHNOLOGY, vol. 2, 1991, pages 266
BIO/TECHNOLOGY, vol. 2, 1991, pages 830
BIO/TECHNOLOGY, vol. 6, 1988, pages 47
BIO/TECHNOLOGY, vol. 9, 1991, pages 266
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960
BIOCHEMISTRY, vol. 15, 1976, pages 5175
BIOCHEMISTRY, vol. 20, 1981, pages 2361
BIOSCIENCE AND INDUSTRY, vol. 50, 1992, pages 322
BIOTECHNOL. BIOENG., vol. 74, 2001, pages 288
BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614
BIOTECHNOLOGY, vol. 2, 1992, pages 358
BLOOD, vol. 65, 1985, pages 1349
BLOOD, vol. 99, 2002, pages 754
BRADY G. ET AL., GENE, vol. 27, 1984, pages 223 - 232
BREKKE O.H. ET AL.: "Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis", MOL. IMMUNOL., vol. 30, no. 16, 1993, pages 1419 - 1425, XP023935453 *
CANCER IMMUNOL IMMUNOTHER., vol. 36, 1993, pages 373
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 373
CANCER IMMUNOL. IMMUNOTHER., vol. 37, 1993, pages 255
CANCER IMMUNOL. IMMUNOTHER., vol. 50, 2001, pages 275
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 36, 1993, pages 373
CANCER RES., vol. 45, 1985, pages 2405
CANCER RES., vol. 45, 1985, pages 2642
CANCER RES., vol. 46, 1986, pages 4116
CANCER RES., vol. 46, 1986, pages 6489
CANCER RES., vol. 47, 1987, pages 1098
CANCER RES., vol. 47, 1987, pages 225
CANCER RES., vol. 48, 1988, pages 6154
CANCER RES., vol. 56, 1996, pages 1118
CANCER RES., vol. 64, 2004, pages 2127
CANCER RESEARCH, vol. 54, 1994, pages 1511
CELL TECHNOLOGY, vol. 12, 1993, pages 239
CELL TECHNOLOGY, vol. 12, 1997, pages 1463
CELL TECHNOLOGY, vol. 13, 1994, pages 255
CELL TECHNOLOGY, vol. 16, 1997, pages 1463
CELL, vol. 33, 1983, pages 717
CELL, vol. 41, 1985, pages 479
CELL, vol. 95, 1998, pages 1017
CHEMICAL IMMUNOLOGY, vol. 65, 1997, pages 88
CHEMISTRY, vol. 46, 1991, pages 681
CLIN. CANCER RES., vol. 10, 2004, pages 6248
CURR. OPIN. ONCOL., vol. 10, 1998, pages 548
CYTOTECHNOLOGY, vol. 1, 1990, pages 133
CYTOTECHNOLOGY, vol. 3, 1990, pages 133
CYTOTECHNOLOGY, vol. 4, 1990, pages 173
DNA CLONING, A PRACTICAL APPROACH, vol. 1, 1985, pages 49
DNA CLONING: A PRACTICAL APPROACH, vol. 1, 1985, pages 49
EUR. J IMMUNOL., vol. 21, 1991, pages 2379
EUR. J. IMMUNOL., vol. 29, 1999, pages 2819
EXPERIMENTAL MEDICINE, vol. 11, 1993, pages 2491
EXPERIMENTAL MEDICINE, vol. 9, 1991, pages 1937
FEBS LETT., vol. 328, 1993, pages 49
GENE THERAPY, vol. 5, 1999, pages 1960
GENE, vol. 200, 1997, pages 149
GENE, vol. 27, 1984, pages 223
GENE, vol. 33, 1985, pages 103
GENE, vol. 34, 1985, pages 315
GENE, vol. 38, 1985, pages 275
GENES DEVELOP., vol. 4, 1990, pages 1288
GENETICS, vol. 39, 1954, pages 440
GILLIES S. D. ET AL., CELL, vol. 33, 1983, pages 717 - 728
HEPATOLOGY, vol. 25, 1997, pages 1462
HUM ANTIB HYBRID, vol. 6, 1995, pages 82
HUM. MOL. GENET., vol. 5, 1995, pages 1083
HUMAN ANTIB HYBRID, vol. 5, 1994, pages 143
IMMUNOL. TODAY, vol. 20, 1999, pages 576
IMMUNOL. TODAY, vol. 21, 2000, pages 364
IMMUNOL. TODAY, vol. 21, 2000, pages 403
IMMUNOL., vol. 85, 1995, pages 668
IMMUNOLOGY, vol. 86, 1995, pages 319
INVEST. DERMATOL., vol. 11 L, 1998, pages 1172
J BACTERIOLOGY, vol. 153, 1983, pages 163
J BIOCHEM., vol. 101, 1987, pages 1307
J BIOL. CHEM., vol. 257, 1982, pages 12752
J BIOL. CHEM., vol. 264, 1989, pages 12122
J BIOL. CHEM., vol. 278, 2003, pages 3466
J CLIN. ONCOL., vol. 17, 1999, pages 2639
J CLIN. ONCOL., vol. 2, 1984, pages 881
J CLIN. ONCOL., vol. 21, 2003, pages 1466
J EXP. MED, vol. 155, 1982, pages 1133
J IMMUNOL. METHODS, vol. 167, 1994, pages 271
J LIQ. CHROMATOGR., vol. 2, 1983, pages 1577
J LIQ. CHROMATOGR., vol. 6, 1983, pages 1577
J MOL BIOL., vol. 16, 1966, pages 118
J MOL, BIOL., vol. 215, 1990, pages 403
J MOL. BIOL., vol. 112, 1977, pages 535
J MOL. BIOL., vol. 16, 1966, pages 118
J MOL. BIOL., vol. 166, 1983, pages 1
J MOL. MED., vol. 75, 1997, pages 829
J NATL. CANCER INST., vol. 80, 1988, pages 937
J. BIOCHEM., vol. 101, 1987, pages 1307
J. BIOCHEM., vol. 95, 1984, pages 197
J. BIOCHEMISTRY, vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 277, 2002, pages 2673
J. CLIN. ONCOL., vol. 16, 1998, pages 2825
J. CLIN. ONCOL., vol. 17, 1999, pages 268
J. IMMUNOL., vol. 135, 1985, pages 1530
J. IMMUNOL., vol. 164, 2000, pages 4178
J. IMMUNOL., vol. 166, 2001, pages 2571
J. IMMUNOL., vol. 172, 2004, pages 3280
J. MOL. BIOL., vol. 166, 1983, pages 1
J. NATL. CANCER INST., vol. 80, 1988, pages 932
J. NUCL. MED, vol. 26, 1985, pages 1011
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, 1991, pages 1025
JOURNAL OFEXPERIMENTAL MEDICINE, vol. 166, 1987, pages 1351
KUWANA Y. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960 - 968
LANCET, vol. 1, 1989, pages 786
LOWE ET AL., PROC. NATL. ACAD SCI. USA, vol. 86, 1989, pages 8227
MASON J. O. ET AL., CELL, vol. 41, 1985, pages 479 - 487
METHODS ENZYMOL., vol. 194, 1990, pages 182
METHODS IN ENZYMOL., vol. 154, 1987, pages 3
METHODS IN ENZYMOLOGY, vol. 154, 1987, pages 3
METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63
MIYAJI H. ET AL., CYTOTECHNOLOGY, vol. 3, 1990, pages 133 - 140
MIYAJI H. ET AL., CYTOTECHNOLOGY, vol. 4, 1990, pages 173 - 180
MIZUKAMI T.; ITOH S., J BIOCHEM., vol. 101, 1987, pages 1307 - 1310
MOL. CELL. BIOL., vol. 3, 1983, pages 280
MOL. IMMUNOL., vol. 30, 1993, pages 1419
MOL. IMMUNOL., vol. 34, 1997, pages 1019
MOL. IMMUNOL., vol. 37, 2000, pages 995
MOL. LMMUNOL., vol. 37, 2000, pages 1035
NAT. BIOTECHNOL., vol. 17, 1999, pages 176
NATURE BIOTECH., vol. 16, 1998, pages 1343
NATURE BIOTECH., vol. 18, 2000, pages 43
NATURE BIOTECH., vol. 18, 2000, pages 555
NATURE BIOTECHNOL., vol. 16, 1998, pages 1015
NATURE CELL BIOL., vol. 2, 2000, pages 70
NATURE GENET., vol. 24, 2000, pages 314
NATURE GENET., vol. 25, 2000, pages 35
NATURE MEDICINE, vol. 4, 1998, pages 285
NATURE REVIEWS CANCER, vol. 1, 2001, pages 119
NATURE, vol. 195, 1962, pages 788
NATURE, vol. 227, 1970, pages 680
NATURE, vol. 312, 1984, pages 643
NATURE, vol. 321, 1986, pages 522
NATURE, vol. 329, 1987, pages 840
NATURE, vol. 332, 1988, pages 323
NATURE, vol. 391, 1998, pages 806
NATURE, vol. 395, 1998, pages 854
NUC. ACIDS RES., vol. 27, 1999, pages 1323
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431
NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 9494
O'HARE K. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 78, 1981, pages 1527 - 1531
ONCOGENE, vol. 22, 2003, pages 7359
PAULSON ET AL., J BIOL. CHEM., vol. 264, 1989, pages 17619
PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 1886
PROC. NATL. ACAD SCI. USA, vol. 79, 1982, pages 6409
PROC. NATL. ACAD SCI. USA, vol. 96, 1999, pages 1451
PROC. NATL. ACAD SCI. USA, vol. 96, 1999, pages 8774
PROC. NATL. ACAD SCI. USA., vol. 89, 1992, pages 4285
PROC. NATL. ACAD. SCI USA, vol. 82, 1985, pages 488
PROC. NATL. ACAD. SCI. (JSA, vol. 82, 1985, pages 488
PROC. NATL. ACAD. SCI. U.S.A, vol. 80, 1983, pages 5392
PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 1242
PROC. NATL. ACAD. SCI. US.A., vol. 78, 1981, pages 1527
PROC. NATL. ACAD. SCI. US.A., vol. 86, 1989, pages 4220
PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 1929
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851
PROC. NATL. ACAD. SCI. USA, vol. 84, 1978, pages 1929
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13959
PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 15502
PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 5049
PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 8768
PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 4285
PROC. NATL. ACAD. SCI., USA, vol. 79, 1982, pages 6409
PROC. NATT. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
PROTEIN ENGINEERING, vol. 7, 1994, pages I501
PROTEIN, NUCLEIC ACID AND ENZYME, vol. 41, 1996, pages 603
SANGER ET AL., PROC. NATL ACAD. SCI. U.S.A., vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD SCI., USA, vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD. SCI. US.A., vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 5463
SCAND. J. IMMUNOL., vol. 32, 1990, pages 517
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 222, 1983, pages 778
SCIENCE, vol. 273, 1996, pages 1386
SHITARA K., J IMMUNOL. METHODS, vol. 167, 1994, pages 271 - 278
SOMATIC CELL MOL, GENET., vol. 12, 1986, pages 555
SOMATIC CELL MOL. GENET., vol. 12, 1986, pages 51
SOSHIKI BAIYO, vol. 20, 1994
SOSHIKI BAIYO, vol. 21, 1995
STRATEGIES, vol. 5, 1992, pages 58
STRATEGIES, vol. 5, 1992, pages 81
STRUCTURE, vol. 8, 2000, pages 2
SUGANO ET AL., GENE, vol. 138, 1994, pages 171
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 132
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 152
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 87
TRENDS IN BIOTECHNOLOGY, vol. 15, 1997, pages 45
VAN LOGHEM E. ET AL.: "Staphylococcal protein A and human IgG subclasses and allotypes", SCAND. J. IMMUNOL., vol. 15, no. 3, 1982, pages 275 - 278, XP008112756 *
VIROLOGY, vol. 8, 1959, pages 396
YAMANE-OHNUKI N. ET AL.: "Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOL. BIOENG., vol. 87, no. 5, 2004, pages 614 - 622, XP002983153 *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010018846A1 (ja) * 2008-08-13 2010-02-18 協和発酵キリン株式会社 ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
RU2606264C2 (ru) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Способ полипептидной модификации для очистки полипептидных мультимеров
JPWO2011078332A1 (ja) * 2009-12-25 2013-05-09 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
US10450381B2 (en) 2010-11-17 2019-10-22 Chugai Seiyaku Kabushiki Kaisha Methods of treatment that include the administration of bispecific antibodies
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2012073985A1 (ja) * 2010-11-30 2012-06-07 中外製薬株式会社 細胞傷害誘導治療剤
US12479929B2 (en) 2010-11-30 2025-11-25 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN109160951A (zh) * 2010-11-30 2019-01-08 中外制药株式会社 细胞毒诱导治疗剂
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US12359001B2 (en) 2015-04-01 2025-07-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity

Also Published As

Publication number Publication date
JPWO2008090960A1 (ja) 2010-05-20
US20110236374A1 (en) 2011-09-29
EP2107115A1 (en) 2009-10-07

Similar Documents

Publication Publication Date Title
WO2008090960A1 (ja) ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
WO2008090958A1 (ja) ドメイン交換された遺伝子組換え抗体組成物
WO2008090959A1 (ja) エフェクター活性が増強された遺伝子組換え抗体組成物
EP1921090A4 (en) COMPOSITION OF GENETICALLY MODIFIED ANTIBODY
CN116322788A (zh) 环状rna组合物和方法
CN105829349B (zh) 肽嵌合抗原受体t细胞开关和其用途
JP2021520192A (ja) 癌に対する三重特異性結合分子及びその使用
JP2022502088A (ja) マスクされたサイトカインポリペプチド
KR101869589B1 (ko) 항-ｃｄ２６ 항체 및 이의 용도
BRPI0717363B8 (pt) imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina
EP3608336B1 (en) Pan elr+ cxc chemokine antibodies
RU2009147758A (ru) Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
AU2011262758A8 (en) Anti-tim-3 antibody
FI2995315T3 (fi) Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon
EP3178847B1 (en) Anti-tnf-alpha fully human monoclonal antibodies with low immunogenicity and application thereof
EP2970467B1 (en) Anti-cd52 antibodies
RU2014147741A (ru) Модифицированные области антител и их применение
WO2010115995A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US20220288226A1 (en) Methods and compositions to treat autoimmune diseases and cancer
CN103772503A (zh) 介白素-6抗体及其用途
TW201438735A (zh) 包括ｇｍ－ｃｓｆ中和化合物之液態配方
EP4204094A1 (en) Methods and compositions to treat autoimmune diseases and cancer
RS60156B1 (sr) Himerni protein sačinjen od ngf antagonist domena i tnfa antagonist domena
WO2004087766A3 (en) Peptabody for cancer treatment
CA3227386A1 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703821

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008555105

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12524215

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008703821

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE